Loading...

Active Biotech

DB:BTPC
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BTPC
DB
SEK479M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Active Biotech AB (publ), a biotechnology company, develops drugs for the treatment of neurodegenerative diseases, autoimmunity/inflammatory, and cancer. The last earnings update was 62 days ago. More info.


Add to Portfolio Compare Print
  • Active Biotech has significant price volatility in the past 3 months.
BTPC Share Price and Events
7 Day Returns
-4.7%
DB:BTPC
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
4%
DB:BTPC
-7.9%
DE Biotechs
-7.2%
DE Market
BTPC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Active Biotech (BTPC) -4.7% -10.6% -25.9% 4% -74.4% -91.8%
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • BTPC outperformed the Biotechs industry which returned -7.9% over the past year.
  • BTPC outperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
BTPC
Industry
5yr Volatility vs Market

BTPC Value

 Is Active Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Active Biotech. This is due to cash flow or dividend data being unavailable. The share price is €0.286.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Active Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Active Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BTPC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-0.27
OM:ACTI Share Price ** OM (2019-04-17) in SEK SEK3.3
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Active Biotech.

DB:BTPC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ACTI Share Price ÷ EPS (both in SEK)

= 3.3 ÷ -0.27

-12.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Active Biotech is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Active Biotech is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Active Biotech's expected growth come at a high price?
Raw Data
DB:BTPC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Active Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Active Biotech's assets?
Raw Data
DB:BTPC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK0.61
OM:ACTI Share Price * OM (2019-04-17) in SEK SEK3.3
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:BTPC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ACTI Share Price ÷ Book Value per Share (both in SEK)

= 3.3 ÷ 0.61

5.45x

* Primary Listing of Active Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Active Biotech is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Active Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Active Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BTPC Future Performance

 How is Active Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Active Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Active Biotech expected to grow at an attractive rate?
  • Unable to compare Active Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Active Biotech's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Active Biotech's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:BTPC Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BTPC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BTPC Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 20 -41 -37
2018-09-30 21 -41 -88
2018-06-30 21 -43 -88
2018-03-31 20 -44 -103
2017-12-31 20 -46 -109
2017-09-30 22 -52 -63
2017-06-30 21 -57 -67
2017-03-31 20 -61 -59
2016-12-31 19 -73 -60
2016-09-30 17 -86 -86
2016-06-30 18 -123 -97
2016-03-31 17 -187 -152

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Active Biotech is high growth as no earnings estimate data is available.
  • Unable to determine if Active Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BTPC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Active Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BTPC Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -0.27
2018-09-30 -0.70
2018-06-30 -0.78
2018-03-31 -1.07
2017-12-31 -1.12
2017-09-30 -0.66
2017-06-30 -0.71
2017-03-31 -0.63
2016-12-31 -0.65
2016-09-30 -0.94
2016-06-30 -1.06
2016-03-31 -1.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Active Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BTPC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Active Biotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Active Biotech's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Active Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Active Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BTPC Past Performance

  How has Active Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Active Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Active Biotech does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Active Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Active Biotech's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Active Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Active Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BTPC Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 20.10 -36.90 10.60 39.30
2018-09-30 20.65 -88.19 11.47 40.45
2018-06-30 20.95 -87.89 11.27 40.45
2018-03-31 20.35 -103.19 18.97 44.65
2017-12-31 20.25 -108.79 20.17 49.35
2017-09-30 21.84 -63.38 20.72 55.55
2017-06-30 20.94 -67.48 21.72 58.15
2017-03-31 19.84 -58.58 15.62 57.85
2016-12-31 19.04 -59.58 15.92 58.25
2016-09-30 16.98 -85.63 16.17 70.63
2016-06-30 18.08 -96.53 16.57 82.43
2016-03-31 17.28 -152.33 17.07 127.83
2015-12-31 16.28 -193.53 17.97 176.23
2015-09-30 14.20 -209.71 17.27 202.29
2015-06-30 11.60 -242.91 17.17 233.39
2015-03-31 11.20 -229.31 17.77 219.99
2014-12-31 10.40 -231.51 16.97 221.89
2014-09-30 11.57 -256.59 17.98 246.82
2014-06-30 115.87 -170.79 17.98 267.52
2014-03-31 115.67 -194.29 17.28 289.72
2013-12-31 115.97 -212.09 16.98 308.02
2013-09-30 203.41 -129.92 17.15 309.28
2013-06-30 136.31 -210.72 16.65 318.78
2013-03-31 227.71 -154.02 16.25 351.08
2012-12-31 227.91 -175.02 15.85 375.28
2012-09-30 139.69 -268.35 15.24 387.97
2012-06-30 102.39 -295.75 15.24 379.27

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Active Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Active Biotech has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Active Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Active Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Active Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BTPC Health

 How is Active Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Active Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Active Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Active Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Active Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Active Biotech Company Filings, last reported 3 months ago.

DB:BTPC Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 87.90 214.50 25.60
2018-09-30 96.80 216.40 36.00
2018-06-30 105.50 218.30 45.60
2018-03-31 67.10 224.10 12.80
2017-12-31 77.68 210.41 25.15
2017-09-30 137.80 205.80 35.60
2017-06-30 146.30 207.30 47.70
2017-03-31 168.70 208.60 62.70
2016-12-31 182.56 216.28 77.68
2016-09-30 141.70 211.60 39.90
2016-06-30 152.20 213.10 57.40
2016-03-31 165.70 214.60 76.50
2015-12-31 180.60 222.76 103.62
2015-09-30 258.40 217.90 132.40
2015-06-30 279.90 219.50 186.60
2015-03-31 349.30 221.00 270.50
2014-12-31 405.31 229.54 328.46
2014-09-30 236.80 231.24 161.00
2014-06-30 291.40 227.10 227.70
2014-03-31 347.20 230.50 298.50
2013-12-31 405.41 235.27 376.20
2013-09-30 485.50 230.00 322.20
2013-06-30 454.30 225.40 389.10
2013-03-31 533.70 226.50 471.30
2012-12-31 339.92 245.38 216.66
2012-09-30 332.40 230.10 308.80
2012-06-30 382.20 231.90 383.70
  • Active Biotech's level of debt (244%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (58.1% vs 244% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Active Biotech has less than a year of cash runway based on current free cash flow.
  • Active Biotech has less than a year of cash runway if free cash flow continues to reduce at historical rates of -61.5% each year.
X
Financial health checks
We assess Active Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Active Biotech has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BTPC Dividends

 What is Active Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Active Biotech dividends.
If you bought €2,000 of Active Biotech shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Active Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Active Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BTPC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Active Biotech has not reported any payouts.
  • Unable to verify if Active Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Active Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Active Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Active Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Active Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Active Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BTPC Management

 What is the CEO of Active Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Helén Tuvesson
COMPENSATION SEK3,540,000
AGE 56
TENURE AS CEO 1.8 years
CEO Bio

Ms. Helén Tuvesson is President and Chief Executive Officer of Active Biotech AB ("Active Biotech"). She has a PhD in medical science from Lund University. She has extensive experience in drug development after more than 20 years on senior positions within Pharmacia and Active Biotech.

CEO Compensation
  • Insufficient data for Helén to compare compensation growth.
  • Helén's remuneration is higher than average for companies of similar size in Germany.
Management Team

Helén Tuvesson

TITLE
President & CEO
COMPENSATION
SEK4M
AGE
56
TENURE
1.8 yrs

Hans Kolam

TITLE
Chief Financial Officer
AGE
67

Helena Eriksson

TITLE
Chief Scientific Officer
AGE
50
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Active Biotech board of directors in years:

14.3
Average Tenure
69.5
Average Age
  • The average tenure for the Active Biotech board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Mats Arnhög

TITLE
Chairman
COMPENSATION
SEK250K
AGE
67
TENURE
16.3 yrs

Peter Sjöstrand

TITLE
Independent Director
COMPENSATION
SEK125K
AGE
72
TENURE
19.3 yrs

Magnhild Sandberg-Wollheim

TITLE
Independent Director
COMPENSATION
SEK125K
AGE
81
TENURE
12.3 yrs

Peter Thelin

TITLE
Independent Director
COMPENSATION
SEK125K
AGE
62
TENURE
7.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Dec 18 Sell East Bay AB Company 18. Dec 18 18. Dec 18 -1,500,000 €0.29 €-435,942
19. Dec 18 Buy Peter Thelin Individual 18. Dec 18 18. Dec 18 1,500,000 €0.29 €435,942
X
Management checks
We assess Active Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Active Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BTPC News

Simply Wall St News

BTPC Company Info

Description

Active Biotech AB (publ), a biotechnology company, develops drugs for the treatment of neurodegenerative diseases, autoimmunity/inflammatory, and cancer. Its product candidates include Laquinimod that is various clinical trials for the treatment of relapsing remitting multiple sclerosis, primary progressive multiple sclerosis, huntington sjukdom, crohns, and lupus diseases; ANYARA, a tumor targeting superantigen, as well as that is combined with a PD-1 inhibitor for advanced cancer; Tasquinimod for the treatment of prostate cancer and multiple myeloma; Paquinimod, an oral immunomodulatory compound for the treatment of systemic sclerosis; and SILC, an S100A9 inhibition by low molecular weight compounds for the treatment of cancer. The company has partnership agreements with Teva Pharmaceutical Industries Ltd and NeoTX Therapeutics Ltd. Active Biotech AB (publ) was incorporated in 1982 and is based in Lund, Sweden.

Details
Name: Active Biotech AB (publ)
BTPC
Exchange: DB
Founded: 1982
SEK45,846,972
145,236,480
Website: http://www.activebiotech.com
Address: Active Biotech AB (publ)
Scheelevägen 22,
Lund,
223 63,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ACTI Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 08. Jun 1995
DB BTPC Ordinary Shares Deutsche Boerse AG DE EUR 08. Jun 1995
LSE 0GQU Ordinary Shares London Stock Exchange GB SEK 08. Jun 1995
BATS-CHIXE ACTIs Ordinary Shares BATS 'Chi-X Europe' GB SEK 08. Jun 1995
Number of employees
Current staff
Staff numbers
14
Active Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 22:05
End of day share price update: 2019/04/17 00:00
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.